Comerica Bank
VRDN icon

Comerica Bank’s Viridian Therapeutics VRDN Stock Holding History

Comerica Bank’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$9.54K Buy
307
+14
+5% +$384 ﹤0.01% 3257
2025
Q3 		$6.31K Buy
293
+10
+4% +$180 ﹤0.01% 3363
2025
Q2 		$3.95K Buy
283
+218
+335% +$2.96K ﹤0.01% 3405
2025
Q1 		$874 Hold
65
– – ﹤0.01% 3574
2024
Q4 		$1.24K Hold
65
– – ﹤0.01% 3548
2024
Q3 		$1.48K Buy
65
+5
+8% +$82 ﹤0.01% 3536
2024
Q2 		$778 Hold
60
– – ﹤0.01% 3600
2024
Q1 		$1.05K Hold
60
– – ﹤0.01% 3619
2023
Q4 		$1.3K Buy
60
+59
+5,900% +$931 ﹤0.01% 3592
2023
Q3 		$14 Buy
+1
New +$19 ﹤0.01% 3784

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Comerica Bank's VRDN Position: Q4 2025 in Review

Comerica Bank increased its Viridian Therapeutics (VRDN) stake by 4.8% in Q4 2025, buying an estimated $384 and bringing the position to 307 shares worth $9.54K. The position accounts for ﹤0.01% of the portfolio, ranked #3257.

Comerica Bank first reported a position in VRDN in Q3 2023 and has held it in 10 quarters since. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Comerica Bank held 307 shares of Viridian Therapeutics worth $9.54K as of Q4 2025.
  • Comerica Bank bought 14 Viridian Therapeutics shares in Q4 2025, an estimated $384.
  • Viridian Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3257 holding.
  • Comerica Bank first reported a position in Viridian Therapeutics in Q3 2023 and has held it in 10 quarters since.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.